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Known germline gene abnormalities cause one-fifth of the pituitary adenomas in children and ado-
lescents, but, in contrast with other pituitary tumor types, the genetic causes of corticotropinomas are
largely unknown. In this study, we report a case of Cushing disease (CD) due to a loss-of-function
mutation in PRKAR1A, providing evidence for association of this gene with a corticotropinoma. A
15-year-oldmalepresentingwithhypercortisolemiawasdiagnosedwithCD.Remissionwasachievedafter
surgical resection of a corticotropin (ACTH)-producing pituitary microadenoma, but recurrence 3 years
later prompted reoperation and radiotherapy. Five years after the original diagnosis, the patient de-
veloped ACTH-independent Cushing syndrome, and a diagnosis of primary pigmented nodular adre-
nocortical disease was confirmed. A PRKAR1A mutation (c.671delG, p.G225Afs*16) was detected in a
germlineDNA sample from the patient, which displayed loss of heterozygosity in the corticotropinoma.No
other germline or somatic mutations of interest were found. As corticotropinomas are not a known
component of Carney complex (CNC), we performed loss of heterozygosity and messenger RNA stability
studies in the patient’s tissues, and analyzed the effect of Prkar1a silencing on AtT-20/D16v-F2 mouse
corticotropinoma cells.NoPRKAR1Adefectswere foundamong97 other pediatricCDpatients studied.Our
clinical case and experimental data support a role for PRKAR1A in the pathogenesis of a corticotroph cell
tumor. This is a molecularly confirmed report of a corticotropinoma presenting in association with CNC.
We conclude that germline PRKAR1A mutations are a novel, albeit apparently infrequent, cause of CD.
Copyright © 2017 Endocrine Society
This article has been published under the terms of the Creative Commons Attribution Non-
Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-
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Loss-of-function germline mutations of the PRKAR1A gene are the main genetic cause of
primary pigmented nodular adrenocortical disease (PPNAD) and Carney complex (CNC) [1].
Pituitary disease is not a rare finding in CNC, but, although the majority of patients develop
subclinical hypersomatotropinemia and/or hyperprolactinemia, only few develop tumors that
require surgery; clinically relevant hyperprolactinemia is infrequent [2, 3]. No other types of
Abbreviations: CD, Cushing disease; CNC, Carney complex; KD, knockdown; MRI, magnetic resonance imaging; PPNAD, primary
pigmented nodular adrenocortical disease; SD, standard deviation.
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pituitary adenomas have been detected to date in this context. We present a case of Cushing
disease (CD) subsequently followed by corticotropin (ACTH)-independent Cushing syndrome
in a patient carrying an inactivatingPRKAR1A germlinemutation, providing evidence for the
role of this gene in corticotroph tumorigenesis.
1. Case Report
A 15.3-year-old African-American male presented with a 6-year history of progressive growth
deceleration [height: 136.7 cm/23.9 standard deviation (SD)] and weight gain (weight: 92.2 kg/
+2.23 SD, body mass index 49.3 kg/m2/+2.99 SD). He had a history of nephrolithiasis diagnosed
18 months before. In the year before his admission, he developed striae; hyperpigmentation of the
upper torso, arms,and face; excessivecorporalhair; easybruising;andheadaches.Duringhis initial
workup, he was diagnosed with hypertension, central hypothyroidism, osteopenia, multiple ver-
tebral compression fractures, bilateral avascular hip necrosis, and retroperitoneal and intraspinal
lipomatosis. Sexual development was adequate for his age (Tanner V for pubic hair and genitalia).
A diagnosis of ACTH-dependent hypercortisolemiawas established on the basis of elevated
midnight serum cortisol (27.5 mg/dL), 24-hour urinary free cortisol (306.8 mg/24 h), and ACTH
(53.05 ng/mL) levels. This was confirmed by the response to CRH stimulation, although the
patient failed to suppress to the high-dose dexamethasone test. Additional results are in-
cluded inTable 1.No lesionwas identified in the pituitarymagnetic resonance imaging (MRI),
but bilateral inferior petrosal sinus sampling demonstrated a high central-to-peripheral
ACTH ratio, compatible with CD. The patient underwent transsphenoidal surgical explo-
ration and resection of a pituitary microadenoma; the pathology report confirmed a corti-
cotropinoma (Fig. 1). Remission was achieved, and, after discharge on glucocorticoid
replacement therapy, the patient experienced substantial improvement of his symptoms.
Recurrence of hypercortisolemia with a possible pituitary lesion by MRI prompted surgical
reintervention 3 years later, but no adenomatous tissue was identified. Due to persistent
hypercortisolemia, the patient was treated with radiotherapy and placed on ketoconazole and
appeared in remission. He was lost to follow-up for 2 years; during that time his disease
progressed, causing uncontrolled hypertension, headaches, and weight gain, as well as further
complications (hypokalemia, nocturnal orthopnea, and urinary and fecal incontinence). A new
diagnostic workup ruled out recurrent CD, but identified ACTH-independent hypercortisolemia
with multiple small nodular bilateral adrenal lesions. Genetic testing identified a frameshift
variant in the PRKAR1A gene. Careful clinical examination revealed numerous lentigines on
the face, oral mucosa, and bulbar conjunctive [Fig. 1(a) and 1(b)], and calcifications compatible
with large-cell calcifying Sertoli cell tumors by ultrasonography. Nomyxomaswere identified in
the echocardiogram or cardiac MRI. The patient underwent bilateral adrenalectomy, and
PPNAD was confirmed [Fig. 1(c)]. Because CD is not a known component of CNC, we
investigated a possible role for PRKAR1A loss-of-function in corticotroph cell tumorigenesis.
2. Materials and Methods
Materials and Methods are presented as Supplemental Material.
3. Results
A. A PRKAR1A Variant Is Associated With a Corticotropinoma in the Setting of CNC
Genetic testing demonstrated a heterozygous frameshift variant of the PRKAR1A gene
(c.671delG, p.G225Afs*16), not previously reported in the public databases or in CNC and/or
PPNAD [Fig. 2(a)]. No other variants of interest in PRKAR1Awere identified among 97 other
pediatric CD patients screened. Mutations in known pituitary disease-causative genes (AIP,
MEN1, CDKN1B, GPR101) and in selected genes involved in the pituitary–adrenal axis
(POMC, GR, MC2R, MC3R, BRG1, CRH, CRHR1, and CRHR2) were ruled out by manual
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Table 1. Additional Hormonal Measurements at Presentation
Basal Hormones
Parameter Result Reference
Insulin 15.4 mU/mL 6–27
TSH 0.16 mU/mL 0.4–4
Free T4 0.9 ng/dL 0.8–1.5
T4 5.1 mg/dL 4.5–12.5
T3 88 ng/dL 90–215
FSH ,0.1 U/L 1–11
LH 0.2 U/L 1–8
Free testosterone 1.5 ng/dL 7.4–22.6
Androstendione 186 ng/dL 65–210 for Tanner V
Dehydroepiandrosterone 2 ng/mL ,6.6
Deydroepiandrosterone sulfate 1.75 ng/dL 0.8–5.6
IGF1 120 ng/dL 171–814 for Tanner V
Midnight salivary cortisol 0.54 mg/dL 0.01–0.09
Dynamic Tests
8 mg Dexamethasone Suppression Test
Time Point Parameter Result
Basal Cortisol 29.3 mg/dL
Final 31.9 mg/dL
CRH Stimulation Test
Time Point Parameter Result
25 min ACTH 45.7 pg/mL
Cortisol 28.8 mg/dL
0 ACTH 51.7 pg/mL
Cortisol 28.2 mg/dL
15 min ACTH 58.5 pg/mL
Cortisol 33.8 mg/dL
30 min ACTH 66.5 pg/mL
Cortisol 30.6 mg/dL
40 min ACTH 66.6 pg/mL
Cortisol 27.9 mg/dL
Bilateral Inferior Petrosal Sinus Sampling
Time Point Parameter Result
25 min ACTH, RPV 40.7 pg/mL
ACTH, LPV 4446 pg/mL
ACTH, peripheral 38.8 pg/mL
0 ACTH, RPV 34.9 pg/mL
ACTH, LPV 3545 pg/mL
ACTH, peripheral 35.7 pg/mL
3 min ACTH, RPV 476 pg/mL
ACTH, LPV 2958 pg/mL
ACTH, peripheral 35.5 pg/mL
5 min ACTH, RPV 300 pg/mL
ACTH, LPV 2737 pg/mL
ACTH, peripheral 33.3 pg/mL
10 min ACTH, RPV 359 pg/mL
ACTH, LPV 2905 pg/mL
ACTH, peripheral 31.8 pg/mL
Abbreviations: FSH, follicle-stimulating hormone; IGF1, insulin-like growth factor1; LH, luteinizing hormone; LVP,
left petrosal vein; RPV, right petrosal vein; TSH, thyrotropin.
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check of whole-exome sequencing raw data. Previous Sanger sequencing and deletion testing
had excluded AIP and MEN1 gene defects in this and additional patients with CD [4].
B. Loss-of-Function of PRKAR1A p.G225Afs*16 Is Due to Messenger RNA Instability
Compared with the peripheral blood-extracted DNA, the corticotropinoma presented loss of
heterozygosity at PRKAR1A, with clear predominance of the mutant allele [Fig. 2(b)]. At the
Figure 1. Clinical and histopathological presentation. (a and b) Small epicanthal lentigines
were observed in this patient. (c) The surgical specimens of bilateral adrenalectomy displayed
the characteristics of PPNAD, and such diagnosis was later confirmed by histopathological
examination. (d) Hematoxylin–eosin staining (203) of the corticotropinoma tissue. The
tumor was a microadenoma measuring approximately 6 3 4 3 2 mm, with Crooke’s cells
surrounding the neoplastic tissue. (e) Breakdown of the reticulin network (203), (f) as well as
strong and diffusely positive ACTH staining (203), was demonstrated. (g) Extensive positive
immunostaining for CAM5.2 was identified (203). (h) Keratin 20 immunostaining was
found in some areas containing Crooke’s cells (203). These images were compatible with
a diagnosis of Crooke’s cell adenoma.
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Figure 2. Role of PRKAR1A in corticotroph cell tumorigenesis, and in PPNAD. (a) The
frameshift PRKAR1A gene (NG_007093.3) variant c.671delG, p.G225Afs*16 affects the exon
7 of the reference transcript (NM_002734.4, the first exon is not translated). The surrounding
region encodes the first of two cyclic adenosine monophosphate–binding domains in the
protein, which are crucial for its regulatory function. (b) The germline mutation identified in
the patient was not present in the mother. As a sample from the father was not available, we
could not determine whether the mutation was inherited from the father or if it appeared as
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messenger RNA level, only the wild-type allele was detected in the PPNAD tissue and
lymphoblastoid cells, supporting messenger RNA instability, and cycloheximide treatment
was insufficient to rescue the expression of themutant allele [Fig. 2(c)].PRKAR1A expression
was significantly reduced in the PPNAD tissue, compared with normal adrenal [Fig. 2(d)]. As
expected from other PRKAR1Amutations in CNC, our data support nonsense-mediated RNA
decay as the mechanism for loss-of-function.
C. Effects of Prkar1a Gene Silencing on Corticotroph Cell Function and Proliferation
Under 30% Prkar1a knockdown (KD), Pomc expression was increased in both the scrambled
control and the KD experiment; only the former reached statistical significance [Fig. 2(e)]. A
trend for lower Trp53 expression was found in the KD compared with the scrambled control.
No significant changes were observed in the expression of other markers of cell cycle
progression.
4. Discussion
Since its first description by Carney and collaborators in 1985,;750 cases of CNC have been
reported [5, 6]. This infrequent, autosomal dominant syndrome (Mendelian Inheritance in
Man: 160980 and 605244) of multiple endocrine neoplasia and cardiocutaneous manifesta-
tions is caused by inactivatingmutations in the PRKAR1A gene (17q24.2) in 73% of the cases,
and by deletions of the 17q24.2-q24.3 region in 6% of the patients [1, 7]. A triplication of the
PRKACB gene at the somatic level was identified as the cause of disease in a single patient,
whereas other cases are linked to an uncharacterized defect in 2p16 [8, 9]. More than half of
the cases display familial presentation, with almost full penetrance [10]. No germline or
somatic PRKAR1Amutations have been identified in sporadic pituitary adenomas [4, 11, 12].
Pituitary disease in CNC consists of single or multiple somatotroph or mammosomato-
troph adenomas, occasionally surrounded by areas of hyperplasia [13–15]. However, a
number of such adenomas in patients with CNC are histologically pleomorphic [16, 17], and
mice with Prkar1a and Rb1 haploinsufficiency develop intermediate lobe tumors [18]. Thus,
although Prkar1a complete deficiency in mouse growth hormone-releasing hormone
receptor–expressing pituitary cells undoubtedly leads to tumors expressing growth hormone,
prolactin, and thyrotropin [19, 20], the data point to the possibility of PRKAR1A deficiency
predisposing to other pituitary tumors as well.
A single patient with CNC possibly having CD has previously been reported [21]. She was
first seen at the age of 3 years with Cushing syndrome and high ACTH levels, although a
pituitary tumor was never proven. She was treated with metyrapone and mitotane and
eventually cured of her disease. Twenty-three years later, she was reported as a patient with
CNC with apparently normal circadian rhythm and cortisol secretion, although biochemical
a de novo event. The PPNAD and nonadenomatous pituitary (obtained from the second
surgery) tissues were heterozygous for such mutation. However, loss of heterozygosity was
identified in the corticotropinoma tissue, with a 72% to 82% predominance of mutant DNA in
the chromatogram peaks measured. (c) In samples from lymphoblastoid cells before and after
the treatment with cycloheximide and in the PPNAD tissue, only the wild-type allele was
detected. Given that these tissues did not display loss of heterozygosity at the DNA level, the
homozygosity for the wild-type allele should be explained by nonsense-mediated messenger
RNA decay. Unfortunately, we did not achieve rescue of the mutant allele during the
cycloheximide experiment performed. (d) Compared with a normal adrenal tissue sample, the
PPNAD specimen displayed significantly reduced Prkar1a expression (mean: 1 6 0.02 vs
0.68 6 0.01, P , 0.0001). (e) We achieved 30% Prkar1a KD compared with the scrambled
control (mean: 0.68 6 0.02 vs 1 6 0.01, P , 0.0001 KD). Compared with the untransfected
cells, Trp53 expression was reduced in the KD experiment (mean: 1.05 6 0.03 vs 0.91 6 0.1,
P = 0.0130), and there was a trend for lower Trp53 in the KD cells compared with the
scrambled control (mean: 1 6 0.05 vs 0.91 6 0.1, P = 0.13). No other significant differences
in the expression of cell cycle markers were found among experimental conditions.
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data were not presented; the patient had the most commonly identified germline PRKAR1A
mutation (c.491_492delTG, p.V164Dfs*5) [1, 21].
The consequence of loss-of-function of the PRKAR1A gene is deregulated activation of the
cyclic adenosine monophosphate pathway due to uncontrolled catalytic subunit activity [6,
22]. This is true for all PRKAR1Amutations causing CNC, even those that are expressed [3,
10, 23, 24]. The mutation described in this patient appears to act the same way, and loss of
heterozygosity in the pituitary tumor further strengthens its causative association.
In conclusion, we describe the association between a newPRKAR1A-inactivatingmutation
and a corticotropinoma in a patient with CNC. This is a documented case with a clinical–
genetic association. No other PRKAR1A defects were found in a large cohort of patients with
CD screened previously [4] and now. Germline PRKAR1Amutations are a notable, although
infrequent, cause of CDmay now be included among the genetic defects that predispose to CD,
albeit rarely.
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